Navigation Links
Coagulation Self-Testing: Devices, Markets, Players and Prospects
Date:8/1/2011

NEW YORK, Aug. 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Coagulation Self-Testing: Devices, Markets, Players and Prospects

http://www.reportlinker.com/p0581170/Coagulation-Self-Testing-Devices-Markets-Players-and-Prospects .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

The ability of patients to self-monitor is deemed to be a critical tool in reducing the pathological effects of difficult-to-control disease factors. For the millions of patients in the US and worldwide prescribed warfarin for oral anticoagulation therapy (OAT), the ability to monitor coagulation rates and adjust drug dosage to optimize therapeutic outcomes is a critical element of patient care. The availability of self-testing monitors provides patients with an opportunity to self-test and avoid frequent caregiver visits. Compared to blood glucose monitoring, OAT self-testing presents a higher level of complexity and risk, placing a premium on patient education. A number of companies are now providing services to patients wishing to self-test, acting as a first-line patient resource and assisting with device selection and patient training. Wirelessly-enabled devices that allow patients to share readings with physicians electronically provide an additional safety and compliance benefit. While still a small percentage of all patients, as demographics and awareness drive increases in the diagnosed incidence of underlying conditions, patient self-testing for OAT will increasingly migrate from caregiver facilities and into homes..

Highlights

• Analyzes marketed patient self-testing devices for measuring and monitoring anticoagulation drug therapy

• Evaluates the status and prospects of coagulation self-test devices currently in development

• Assesses the market potential and commercialization risks and opportunities for coagulation self-test devices

• Examines the role and impact of third-party PT/INR self-test services on device demand and patient acceptance

• Provides market data and forecasts to 2015

• Profiles market participants, their technology, product development activity, and business strategies

Executive Summary

Anticoagulation Therapy Market Dynamics

Anticoagulation Economics

Oral Anticoagulation Therapy

Monitoring Prothrombin Time

Competing Anticoagulation Tests

Key Factors in Patient Compliance

Market Drivers

Industry Alignment and Competitive Landscape

Coagulation Self-Testing Device Design Factors

Standardization of PT/INR Testing

Accuracy and Precision

Sampling Method

Endpoint Detection

Patient/User Interface

Connectivity & Data Collection

Commercialization Factors

Managed Care and Reimbursement

Patient Training and Education

Third-Party Self-Testing Services

Market Factors

Regulations and Standards

Patient/Consumer Sentiment

Regional Demand and Demographics

Alliances and Partnerships

Proprietary Technology

Patient Self-Testing Product Assessments

CoaguChek

CoaguSense

InRatio

ProTime

Development-Stage Devices

iLine Microsystems

Microvisk

Universal Biosensors

Zin Technologies

Market Analysis, Data and Forecasts

Indications and Demographics

Therapeutic Market Segments

New Technology & Pipeline Prospects

Geographic Markets

Market Participant Profiles

To order this report:

In Vitro Diagnostic Industry: Coagulation Self-Testing: Devices, Markets, Players and Prospects

In Vitro Diagnostic Business News

More  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
2. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
3. Reportlinker Adds The 2011 US Coagulation Market
4. Roche Introduces CoaguChek Link Web Resource to Streamline Anticoagulation Management for Doctors and Patients
5. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
6. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
7. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
8. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
9. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
10. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  Ampio Pharmaceuticals, Inc. (NYSE MKT: ... entered into a Controlled Equity Offering SM Sales ... Michael Macaluso , Chairman and CEO, stated "During ... are not currently raising money and that we have ... 2017 and still complete all of our current objectives ...
(Date:2/11/2016)... Germany , February 11, 2016 ... up 6.8% to EUR 1,377.2m  Adjusted EBITDA climbs to ... 18.0% to EUR 3.41  Proposed dividend of EUR 0.85 ... sale of glass tubing business and refinancing successfully completed  ... to 5% on organic basis  Adjusted EBITDA expected ...
(Date:2/10/2016)... REDWOOD CITY, Calif., Feb. 10, 2016   Genomic Health, Inc. ... progress for the quarter and year ended December 31, 2015. ... in the fourth quarter of 2015, compared with $69.1 million in ... a constant currency basis, revenue increased 9 percent compared with the ... --> U.S. revenue was $63.9 million in the fourth ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... The Commission for ... the Board of Commissioners. Individuals interested in volunteer board service are encouraged to ... clinical practice settings and across allied health to contribute to its mission and ...
(Date:2/11/2016)... ... February 11, 2016 , ... Greenfield Insurance Group in Orange ... assist the people of their local community. The agency pledges to select a ... Their hope is to bring awareness to important local causes with fundraising and ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... ongoing community involvement program, introduces a new charity campaign to raise funds for ... now being accepted at https://donate.rmhc.org/ . , Ronald McDonald House (RMH) is ...
(Date:2/11/2016)... ... , ... Be Well Medical Group (Be Well) is pleased to ... 108 South Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group is a ... convenience of their homes, offices or at the practices’ local office. It is also ...
(Date:2/11/2016)... ... February 11, 2016 , ... Food Labeling for ... health and wellness best practices in the past couple of decades, and food ... American Heart Month, which acts as an exceptional opportunity to revise food labels ...
Breaking Medicine News(10 mins):